3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Rectal Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Glioma
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Astrocytoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Lung Neoplasms
2
Carcinoma, Squamous Cell
2
Brain Neoplasms
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Sinonasal Squamous Cell Carcinoma
1
Rhabdomyosarcoma
1
Recurrence
1
Radiation Injuries
1
Prostatic Neoplasms
1
Prostate Adenocarcinoma
1
Postoperative Complications
1
Pilonidal Sinus
1
Interventions
pembrolizumab
8
cemiplimab
5
Nivolumab
4
Ipilimumab
4
Blood Specimen Collection
3
lifileucel
2
avelumab
2
aldesleukin
2
Niacinamide
2
Cyclophosphamide
2
toripalimab
1
tislelizumab
1
oxycodone-acetaminophen
1
lenvatinib
1
fludarabine
1
epacadostat
1
encorafenib
1
durvalumab
1
dostarlimab
1
brodalumab
1
binimetinib
1
atezolizumab
1
Vitamin A
1
Surgical Procedures, Operative
1
Sunscreening Agents
1
Standard of Care
1
Specimen Handling
1
Resistance Training
1
Radiotherapy
1
Niacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
Surgical Procedures, Operative
×
90 days
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled